论文部分内容阅读
目的:研究参苓胶囊对小鼠移植性肿瘤S_(180)肉瘤,H_(22)肝癌和Lewis肺癌的抗肿瘤作用及对环磷酰胺(CTX)所致小鼠免疫功能抑制的保护作用。方法:根据抗癌药物筛选标准进行体内抑瘤试验。采用CTX制备免疫功能低下模型,测定参苓胶囊与CTX配伍对小鼠白细胞数、胸腺指数、脾指数和NK细胞活性的影响。结果:不同浓度的参苓胶囊对小鼠移植性肿瘤S_(180)肉瘤,H_(22)肝癌和Lewis肺癌均有抑制作用,其中高剂量组效果最佳,抑制率分别为44.8%,52.2%,43.3%(P<0.01),且对小鼠体重生长无明显影响。参苓胶囊可明显减少CTX所致的小鼠白细胞下降,免疫器官重量和NK细胞活性降低等副作用。结论:参苓胶囊具有明显的抗肿瘤和免疫增强作用。
Objective: To study the anti-tumor effects of Shenqi capsule on transplanted tumors of mouse S 180 sarcoma, H 22 hepatocarcinoma and Lewis lung cancer, and the protective effect of cyclophosphamide (CTX)-induced immune suppression in mice. Methods: In vivo anti-tumor tests were performed according to anti-cancer drug screening criteria. CTX was used to prepare the immunocompromise model, and the effects of compatibility of Shenqi capsules and CTX on WBC count, thymus index, spleen index and NK cell activity were measured. RESULTS: Shenqi capsules with different concentrations had inhibitory effects on transplanted tumor S 180 sarcoma, H 22 hepatocarcinoma and Lewis lung carcinoma. Among them, the high dose group had the best effect, with inhibition rates of 44.8% and 52.2%, respectively. 43.3% (P<0.01), and no significant effect on body weight growth in mice. Shenqi capsules can significantly reduce CTX-induced decline in white blood cells, immune organ weight and NK cell activity and other side effects. Conclusion: Shenqi capsule has obvious anti-tumor and immune enhancement effects.